Genetron Health Receives CAP Accreditation for its Maryland Laboratory
15 Juin 2022 - 12:00PM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced College of American Pathologists (CAP)
Accreditation for its laboratory in Maryland, U.S.
CAP Accreditation is designed to help laboratories maintain the
accuracy of test results and ensure accurate patient diagnosis,
meet required regulatory standards and maintain industry-leading
best practices. The Maryland laboratory joins the Company’s main
lab in Beijing as its second lab that is both CAP and CLIA
accredited. With the accreditation the company strengthens its US
arm of drug development services conducting discovery and
translational research, clinical trial execution and corresponding
companion diagnostics development.
“We are proud to be one of the few select genomic profiling
companies to achieve validation of our lab quality and regulatory
practices through CAP Accreditation in both China and the US,” said
Yun-Fu Hu, Chief Medical Officer of Genetron. “This designation
further differentiates our global drug development service offering
and positions Genetron to better support the global clinical trials
needs of our global and domestic biopharmaceutical partners.”
Genetron Health offers comprehensive drug development services
to global biopharmaceutical companies encompassing genomic testing
for pre-clinical biomarker evaluation, clinical trial enrollment
and execution, companion diagnostics development and registration.
Genetron Health has partnered with NeoGenomics, Inc and dMed
Biopharmaceutical to support global oncology drug research and
development in both China and the U.S. for pharmaceutical
companies.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq:GTH) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Statements that
are not historical facts, including statements about the Company’s
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties, and a number of factors could cause actual results
to differ materially from those contained in any forward-looking
statement. In some cases, forward-looking statements can be
identified by words or phrases such as “may”, “will,” “expect,”
“anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “potential,” “continue,” “is/are likely to” or other
similar expressions. Further information regarding these and other
risks, uncertainties or factors is included in the Company’s
filings with the SEC. All information provided in this press
release is as of the date of this press release, and the Company
does not undertake any duty to update such information, except as
required under applicable law.
Investor Relations ContactEmail: ir@genetronhealth.com
Media Relations ContactYanrong ZhaoEmail:
yanrong.zhao@genetronhealth.com
Genetron (NASDAQ:GTH)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Genetron (NASDAQ:GTH)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024